{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:26:34Z","timestamp":1794626794954,"version":"4.9.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijgc.2025.101823","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T03:02:49Z","timestamp":1744340569000},"page":"101823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The new 2023 endometrial cancer FIGO staging system: balancing innovation with complexity"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6566-2502","authenticated-orcid":false,"given":"Emilia","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8059-1602","authenticated-orcid":false,"given":"Andrea","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":false,"given":"Robert","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3576-601X","authenticated-orcid":false,"given":"Sigurd","family":"Lax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-6605","authenticated-orcid":false,"given":"Xavier","family":"Matias-Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-1581","authenticated-orcid":false,"given":"David","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-9041","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Stolnicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-9645","authenticated-orcid":false,"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Concin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijgc.2025.101823_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ijgc.2025.101823_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2024.02.002","article-title":"2023 FIGO staging system for endometrial cancer: the evolution of the revolution","volume":"184","author":"Gaffney","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101823_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2024.01.040","article-title":"2023 changes to FIGO endometrial cancer staging: counterpoint","volume":"184","author":"Leitao","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101823_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113317","article-title":"Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - an international pooled analysis of three ESGO accredited centers","volume":"193","author":"Schwameis","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2025.101823_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113316","article-title":"Validation of the 2023 FIGO staging schema for advanced endometrial cancer","volume":"193","author":"Matsuo","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2025.101823_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113318","article-title":"New FIGO 2023 endometrial cancer staging validation. Welcome to the first molecular classifiers and new pathological variables","volume":"193","author":"Vergote","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2025.101823_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2023.05.069","article-title":"The right time for change: a report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria","volume":"175","author":"Haight","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101823_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2023.09.011","article-title":"Utility of the revised FIGO2023 staging with molecular classification in endometrial cancer","volume":"178","author":"Kobayashi-Kato","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101823_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113913","article-title":"Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer","volume":"201","author":"Gravbrot","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101823_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/ijgc-2023-004981","article-title":"FIGO 2023 endometrial cancer staging: too much, too soon?","volume":"34","author":"McCluggage","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101823_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/his.15302","article-title":"Prognostic performance of FIGO 2023 endometrial carcinoma staging: a comparison to FIGO 2009 staging in the setting of known and unknown molecular classification","volume":"85","author":"Libert","year":"2024","journal-title":"Histopathology"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101823_bib12","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3390\/medicina60091421","article-title":"External validation of the new 2023 International Federation of Gynecology and Obstetrics staging system in endometrial cancer patients: 12-year experience from an European society of gynecological oncology-accredited center","volume":"60","author":"Tsolakidis","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101823_bib13","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1186\/s12885-024-12633-8","article-title":"Clinical application of FIGO 2023 staging system of endometrial cancer in a Chinese cohort","volume":"24","author":"Yu","year":"2024","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101823_bib14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/00000478-200009000-00002","article-title":"A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis","volume":"24","author":"Lax","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"5-6","key":"10.1016\/j.ijgc.2025.101823_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000082917","article-title":"The reproducibility of a binary tumor grading system for uterine endometrial endometrioid carcinoma, compared with FIGO system and nuclear grading","volume":"67","author":"Sagae","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.ijgc.2025.101823_bib16","article-title":"WHO Classification of Tumours Editorial Board","year":"2020","journal-title":"International Agency for Research on Cancer"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101823_bib17","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-23-1397","article-title":"Clinical behavior and molecular landscape of stage I p53-abnormal low-grade endometrioid endometrial carcinomas","volume":"29","author":"Jamieson","year":"2023","journal-title":"Clin Cancer Res."},{"issue":"7","key":"10.1016\/j.ijgc.2025.101823_bib18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41379-019-0220-1","article-title":"Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma","volume":"32","author":"Yano","year":"2019","journal-title":"Mod Pathol."},{"issue":"5","key":"10.1016\/j.ijgc.2025.101823_bib19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of Grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ijgc.2025.101823_bib20","article-title":"Risk stratification of Stage I Grade 3 endometrioid endometrial carcinoma in the era of molecular classification","volume":"6","author":"Zammarrelli","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101823_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101823_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/his.15272","article-title":"Practical guidance for assessing and reporting lymphovascular space invasion (LVSI) in endometrial carcinoma","volume":"86","author":"Peters","year":"2024","journal-title":"Histopathology"},{"issue":"13","key":"10.1016\/j.ijgc.2025.101823_bib23","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ejca.2015.05.015","article-title":"Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--a pooled analysis of PORTEC 1 and 2 trials","volume":"51","author":"Bosse","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101823_bib24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.brachy.2020.12.006","article-title":"Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancer","volume":"20","author":"Barnes","year":"2021","journal-title":"Brachytherapy"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101823_bib25","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/ijgc-2024-005746","article-title":"Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study","volume":"34","author":"Dagher","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.101823_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2024.06.009","article-title":"The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma","volume":"188","author":"Bhatnagar","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101823_bib27","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101823_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.101823_bib29","first-page":"2025","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma - Update 2025","author":"Concin","year":"2025","journal-title":"Lancet Oncol, forthcoming"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101823_bib30","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2021.32.e11","article-title":"Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer","volume":"32","author":"Tortorella","year":"2021","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101823_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2020.10.011","article-title":"Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: prognostic and clinical implications","volume":"142","author":"Restaino","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2025.101823_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ygyno.2024.01.046","article-title":"Prognostic value of three-tiered scoring system for lymph-vascular space invasion in endometrial cancer: a systematic review and meta-analysis","volume":"184","author":"Han","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101823_bib33","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1136\/ijgc-2023-004606","article-title":"Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer","volume":"33","author":"Siegenthaler","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101823_bib34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ygyno.2022.01.007","article-title":"Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment","volume":"164","author":"Leon-Castillo","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101823_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/PGP.0000000000000805","article-title":"Substantial lymphovascular space invasion is an adverse prognostic factor in high-risk endometrial cancer","volume":"41","author":"Peters","year":"2022","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101823_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/PGP.0000000000000806","article-title":"Defining substantial lymphovascular space invasion in endometrial cancer","volume":"41","author":"Peters","year":"2022","journal-title":"Int J Gynecol Pathol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101823_bib37","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy","volume":"119","author":"Wortman","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101823_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/his.13871","article-title":"Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer","volume":"75","author":"Peters","year":"2019","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101823_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100251","article-title":"Lymphovascular space invasion in endometrial cancer molecular era: a large, retrospective, tertiary center analysis","volume":"35","author":"Perrone","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101823_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101823_bib41","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101823_bib42","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101823_bib43","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.ijgc.2025.101823_bib44","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2025.101823_bib45","doi-asserted-by":"crossref","unstructured":"Valabrega G, Powell MA, Hietanen S, et al. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient\/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO\/GOG3031\/RUBY trial. Int J Gynecol Cancer. Published online January 6, 2025. doi:10.1136\/ijgc-2024-005484.","DOI":"10.1136\/ijgc-2024-005484"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101823_bib46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"issue":"29","key":"10.1016\/j.ijgc.2025.101823_bib47","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ijgc.2025.101823_bib48","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101823_bib49","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-15-2233","article-title":"Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis","volume":"22","author":"McConechy","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101823_bib50","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/jnci\/dju402","article-title":"Prognostic significance of POLE proofreading mutations in endometrial cancer","volume":"107","author":"Church","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101823_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101823_bib52","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1016\/S1470-2045(24)00192-X","article-title":"Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer Intergroup","volume":"25","author":"Creutzberg","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101823_bib53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/gyno.1997.4732","article-title":"Surgical staging of endometrial cancer: evolution, evaluation, and responsible challenge--a personal perspective","volume":"66","author":"Boronow","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"7447","key":"10.1016\/j.ijgc.2025.101823_bib54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101823_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2007.07.018","article-title":"New development of the FIGO staging system","volume":"107","author":"Odicino","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101823_bib56","series-title":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Head and Neck Cancers. V.4.2024","year":"2024"},{"key":"10.1016\/j.ijgc.2025.101823_bib57","series-title":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Thyroid Carcinoma. V.3","year":"2024"},{"key":"10.1016\/j.ijgc.2025.101823_bib58","series-title":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancers. V.2","year":"2024"},{"key":"10.1016\/j.ijgc.2025.101823_bib59","series-title":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Melanoma: Cutaneous. V.2. 2024","year":"2024"},{"key":"10.1016\/j.ijgc.2025.101823_bib60","series-title":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Uterine Cancers. V.2. 2024","year":"2024"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:42:23Z","timestamp":1785548543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25009429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1048891X25009429"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101823","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The new 2023 endometrial cancer FIGO staging system: balancing innovation with complexity","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101823"}}